room revenu out-performance capit deploy addl upsid
morn baxter report result beat top bottom line
compani maintain cc oper revenu guidanc rais adj ep
midpoint margin improv stori continu drive share
beyond believ investor may overlook revenu growth opportun
within manag continu execut plan stock close
lower today print like due headwind medic deliveri nutrit
view guidanc manag provid conserv room upsid
manag discuss intent deploy capit accret though
share repurchas continu meantim see larg share appreci
potenti capit deploy year come year consequ
result set-up continu encourag investor start build posit
result report sale beat street
essenti in-lin target constant currenc basi grew vs
street model oper growth ex us cyclo acquisit
currenc line guidanc gross margin bp
street op margin miss adjust cash ep
beat street
cc oper revenu guidanc maintain adj ep guidanc rais
report basi compani brought full year sale guidanc given
strengthen dollar previous reaffirm expect
constant currenc basi growth oper basi op margin
expans annual maintain bottom line rais full
year ep guidanc mostli due lower tax rate vs
previous street model guidanc call
report revenu growth cc oper basi adjust
ep guidanc
point call term call manag discuss better
expect growth quarter broad base standout
pharmaceut busi cc vs street
medic deliveri segment cc miss street
former benefit increas inject sale us clari acquisit
contribut quarter medic deliveri perform impact
lower sale svp unabl ramp back pre-hurrican suppli level
though expect improv come week manag address
fda warn letter reiter make proper invest facil
materi impact lrp issu analyst day
price pressur gener competit deal execut
price close juli
ebitda
assum net debt s/o
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
term guidanc believ room bit upsid given market develop new
product flow increas invest collect augment organ revenu
growth particularli strong cadenc inject launch intern develop molecul
well clari deal realli key us go forward innov
deliv new product expect next five year investor feel
comfort base busi irrespect deal continu acceler lrp
call compound-annual-growth-rate compound-annual-growth-rate
lastli perhap importantli compani reiter commit capit
deploy impli focu find accret deal share repurchas though
later continu strong clip meantim compani one strongest
balanc sheet med tech current neutral cash/debt along project cash
flow deploy next five year given manag previou track record
integr asset bolster copor growth rate provid accret bottom
line embed guidanc deal would increment number
manag set
stock stock close lower today print like due
headwind medic deliveri nutrit view guidanc manag provid
conserv room upsid believ stock continu lift new
product ramp back half year manag execut margin
improv addit potenti substanti catalyst share
recommend investor establish posit weak given high qualiti franchis
lastli rais price target roll ev/ebitda multipl
forward target base ebitda assum
net debt s/o
page
page
 gener incom expens net incom tax net analysi gross gener oper
million
sale
market administr
revenu report
percent sale
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
